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Abstract
Background: Current blood based diagnostic assays to detect heart failure (HF) have large intra-individual and inter-
individual variations which have made it difficult to determine whether the changes in the analyte levels reflect an actual
change in disease activity. Human saliva mirrors the body’s health and well being and ,20% of proteins that are present in
blood are also found in saliva. Saliva has numerous advantages over blood as a diagnostic fluid which allows for a non-
invasive, simple, and safe sample collection. The aim of our study was to develop an immunoassay to detect NT-proBNP in
saliva and to determine if there is a correlation with blood levels.
Methods: Saliva samples were collected from healthy volunteers (n = 40) who had no underlying heart conditions and HF
patients (n = 45) at rest. Samples were stored at 280uC until analysis. A customised homogeneous sandwich AlphaLISA(R)
immunoassay was used to quantify NT-proBNP levels in saliva.
Results: Our NT-proBNP immunoassay was validated against a commercial Roche assay on plasma samples collected from
HF patients (n = 37) and the correlation was r2 = 0.78 (p,0.01, y = 1.7056+1910.8). The median salivary NT-proBNP levels in
the healthy and HF participants were ,16 pg/mL and 76.8 pg/mL, respectively. The salivary NT-proBNP immunoassay
showed a clinical sensitivity of 82.2% and specificity of 100%, positive predictive value of 100% and negative predictive
value of 83.3%, with an overall diagnostic accuracy of 90.6%.
Conclusion: We have firstly demonstrated that NT-proBNP can be detected in saliva and that the levels were higher in heart
failure patients compared with healthy control subjects. Further studies will be needed to demonstrate the clinical relevance
of salivary NT-proBNP in unselected, previously undiagnosed populations.
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Introduction
Heart failure (HF) is a global health problem, associated with
poor clinical outcomes and substantial economic burden to the
healthcare system [1,2]. Approximately, 23 million people
worldwide are living with HF [2]. The population estimates of
HF prevalence ranges between 2 and 10%, with a higher
prevalence in the elderly [3].
Plasma/serum concentrations of natriuretic peptides, N-termi-
nal proB-type natriuretic peptide (NT-proBNP, 76 AA) or B-type
natriuretic peptide (BNP, 32 AA) are currently used to diagnose
HF [4–7]. Several companies including Roche Diagnostics
commercialise NT-proBNP immunoassays targeting various frag-
ments of the NT-proBNP molecule (middle part of the NT-
proBNP molecule is glycosylated). Therefore, the NT-proBNP
results are not comparable across laboratories [8–10]. Current
blood-based ‘sandwich’ immunoassays use monoclonal and
polyclonal antibodies targeting different epitopes to quantify
plasma levels of NT-proBNP and BNP [11–14]. This may
complicate interpretation of plasma levels of NT-proBNP/BNP
for diagnosing and monitoring HF, especially if a patient accesses
different laboratory services that use different assays/platforms.
These differences will only be minimised with improved under-
standing of the molecular forms and glycosylation patterns of NT-
proBNP and BNP in the circulation.
Human saliva composition reflects our body’s health and well
being and about 20% of proteins that are present in the blood are
also found in saliva [15], which highlights the diagnostic potential
of saliva. Saliva does not clot like blood, and its collection is non-
invasive [16–18]. Saliva samples are relatively easy to handle in
comparison to blood collection and processing thereby decreasing
the risk of contracting blood-borne infectious organisms [19–21].
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Furthermore, avoiding the need for a phlebotomist enables
multiple saliva sample collections within a day by unskilled people.
The half-life of BNP is approximately 20 minutes and that of
NT-proBNP is around 60–90 minutes [22,23]. Hence, NT-
proBNP clearance from blood is slower than its counterpart
BNP, allowing possible movement of the former molecule into
the saliva through various routes, but mainly via the gingival
crevicular fluid [24]. We hypothesise that the relatively long
half-life of NT-proBNP in circulation enables substantial
movement of NT-proBNP from blood into saliva. The aims
of our study were to develop an immunoassay to detect NT-




This research was approved by the University of Queensland
Medical Ethical Institutional Board and the Mater Hospital
Medical Ethical Review Board. All participants were .18 years of
age and gave written informed consent before donating samples
for our study. We recruited two cohorts of volunteers: patients with
symptoms and/or signs of HF at varying clinical stages (with left
ventricular ejection fraction ,40%) from a general cardiology
department and healthy control subjects. HF diagnosis was
confirmed by the cardiologist from Mater Adult Hospital
according to the Guidelines for the prevention, detection and
management of chronic HF in Australia [5]. Patients with
concomitant disease states that might alter salivary NT-proBNP
concentrations (e.g. rheumatoid arthritis, inflammatory bowel
disease, Sjogren’s syndrome, Raynaud’s disease) were excluded.
All subjects were asked to refrain from exercise for 24 hours prior
to sample collection. Exclusion criteria included the existence of
any comorbid oral disease (e.g periodontal disease and gingivitis),
autoimmune, infectious, musculoskeletal disease, malignancy, and
recent operation or trauma. The subjects were of European,
African and Asian descent, and had no symptoms of fever and/or
respiratory tract infection. The salivary NT-proBNP and plasma
concentrations from the HF patients were then compared with the
clinical diagnostic criteria used by cardiologists in order to
determine the diagnostic utility of the salivary NT-proBNP
immunoassay.
2.2 Samples
Blood samples were collected into EDTA tubes (Greiner
VACUETTEH # 454023, Greiner Bio-one, Graz, Austria) and
then immediately centrifuged at 30006g at RT for 10 minutes.
The plasma samples were divided into aliquots, and stored at
280uC until analysed. Saliva samples were collected in sterile
urine containers (Sarstedt, Australia) and stored at 280uC until
analysed.
For salivary protein analysis, unstimulated saliva is the
preferred method [18,21]. Unstimulated resting saliva was
collected by the draining or drooling method described by
Navazesh and Christensen [25,26]. Volunteers were asked to
rinse their mouth with water prior to donating saliva. This
ensured minimal debris from food particles and that the oral
cavity was well hydrated to enhance saliva production. The
samples were collected and placed on ice, then transported to
the laboratory on dry ice. The samples were aliquoted, de-
indentified, and stored at 280uC until analysis.
2.3 Salivary NT-proBNP AlphaLISA(R) Immunoassay
The NT-proBNP AlphaLISA(R) kit (Product-No: 1607106,
Perkin ElmerH, MA, USA), was used to determine the concentra-
tions of salivary NT-proBNP. It contains a biotinylated anti-NT-
proBNP monoclonal antibody (recognising 1–12 AA sequences
on the NT-proBNP analyte), which binds to the streptavidin-
coated donor beads while the anti-NT-proBNP monoclonal
antibody (recognising 63–76 AA) is conjugated to the acceptor
beads. In the presence of NT-proBNP, the beads come into
close proximity. The total reaction volume used was 10 mL.
Twelve standards were used to generate a standard curve. The
samples were analysed in triplicates in 384 well ProxiPlatesTM
(Perkin ElmerH, MA, USA). The only exception to the
manufacturer recommendation was the decrease in the total
reaction volumes from 50 mL to 10 mL. In summary, the
immunoassay consisted of sample/analyte (1 mL), biotinylated
antibody (25 mM) and acceptor bead (25 mg/mL) mix, and
streptavidin donor beads (80 mg/mL). For all immunoassays, the
end concentration of acceptor beads was 10 mg/mL whilst the
end concentration of biotinylated antibody was 1 nM. The total
incubation time was 1.5 hour at room temperature in the dark
and the plates were read using an EnSpireTM plate reader
(Perkin ElmerH, MA, USA).
Table 1. Characteristics of HF patients and healthy controls.
Parameter HF patients (n=45) Healthy controls (n=40) Statistics
Age 73 (53–88) 56 (40–71) PM,0.0001*
Gender (M: F) 23:22 20:20 PC = 0.919
Body Mass index (kg/m2) 29.14 (20–42.6) 25 (20–37) PM = 0.0194*
NYHA Classification 3 0 PM,0.0001*
Systolic blood pressure (mm Hg) 125 (93–158) n/a n/a
Diastolic blood pressure (mm Hg) 71 (45–86) n/a n/a
Heart rate (bpm) 71 (46–80) n/a n/a
Results are shown as median (min-max) for the data without normal distribution.
PM =p-value for 2-tailed Mann-Whitney U test.
PC = p-value for 2-sided Chi-square test.
*Significant at 0.05 level.
n/a =Not applicable.
doi:10.1371/journal.pone.0048452.t001
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2.4 The Concentration of Saliva Samples Using Amicon
Filters
Saliva samples collected from both HF patients and healthy
controls required concentration. Saliva (200 mL) was centrifuged
using the Amicon Ultra-0.5 Centrifugal Filter Devices at 140006g
for 20 minutes. The concentrated solution was recovered by
placing the Amicon filter device upside down into a clean micro
centrifuge tube and NT-proBNP levels were measured using
AlphaLISA (R) immunoassay.
2.5 Assay Performance Characteristics of the NT-proBNP
AlphaLISA(R) Immunoassay
2.5.1 Recovery. To evaluate the suitability of AlphaLISA(R)
immunoassay for measuring salivary NT-proBNP, three known
concentrations of commercial recombinant NT-proBNP (Product-
No: 1607106, Perkin ElmerH, MA, USA) were spiked in pooled saliva
collected from healthy controls (n = 40). Both spiked and un-spiked
pooled saliva were measured in the same AlphaLISA(R) immuno-
assay. The percentage recovery of the three spiked saliva sample
was calculated in reference to respective un-spiked pooled saliva
sample in a single AlphaLISA(R) immunoassay, using the following
equation [27]:
Percentage recovery %ð Þ
~
NT-proBNP concentration in spiked saliva
NT-proBNP concentration in un-spiked saliva
 !
=amount of spikedNT-proBNP  100%
2.5.2 Intra-and inter-assay coefficient of variation. To
determine intra- and inter- assay variation, triplicates of saliva
samples from 45 HF patients and 40 healthy controls were run in
one AlphaLISA(R) immunoassay and three independent AlphaLI-
SA(R) immunoassay, respectively [27].
2.5.3 Limit of detection (LOD) of NT-proBNP
immunoassay. To determine the LOD of the NT-proBNP
immunoassay, 16 blanks (without the NT-proBNP analyte) were
run in triplicates in one immunoassay. The LOD for the salivary
NT-proBNP immunoassay was read from a sigmoidal-dose
response curve based on LOD signal counts derived from the
equation [28]:
LODsignal count~ average of blank signal countð Þ
z 3| standard deviation of blank signal countð Þ
2.6 Statistical Analysis
All statistical analyses were performed using GraphPad Prism 5
software version 5.03 (GraphPad Software Inc., USA). A standard
curve was generated by plotting the ‘‘raw’’ AlphaLISA counts vs
the NT-proBNP standards using a 4-parameter logistic equation
(sigmoidal dose-response curve with variable slope) and a 1/Y2
data weighting.
Kolmogorov-Smirnov statistic was performed on clinical
characteristics (continuous variables) of the volunteers, in order
to test for normal distribution before statistical analyses. To
compare values from two groups, Mann-Whitney U test was
performed on data without normal distribution [29] and Chi-
square test for dichotomous variables. Statistical significance for
differences between HF and healthy subjects was considered
significant at or below p,0.05 and was calculated using the
GraphPad Prism program. Pearson product moment correlation
coefficients were calculated to investigate the relationship between
salivary and plasma NT-proBNP levels. Diagnostic accuracy
expressed as sensitivity, specificity, positive predictive value and
negative predictive value were obtained from a 262 table with the
reference standard based upon clinical diagnosis of heart failure (as
described in Section 2.1).
Results
3.1 Participants
In total 45 symptomatic HF patients (with left ventricular
ejection fraction ,40%) and 40 healthy volunteers (young, and
old) were enrolled in the study. The group of HF patients consisted
of 23 males and 22 females, with a median age of 73 years (ages
from 53 to 88), body mass index (BMI) of 29.14, and systolic and
diastolic blood pressure of 125 mm Hg and 71 mm Hg, respec-
tively. The group of healthy controls consisted of 20 males and 20
females, with a median age of 56 years (ages from 40 to 71) and
BMI of 25. Gender, age, BMI, blood pressure, heart rate, New
York Heart Association (NYHA) classification of the 85 volunteers
were summarised in Table 1.





(± Std error) Limit of detection (LOD)
NT-proBNP 85% 7.17 (0.75) 4.46 (0.59) 16 pg/mL
doi:10.1371/journal.pone.0048452.t002
Figure 1. Comparison of the NT-proBNP immunoassay when
compared with a commercially available diagnostic assay
(Roche Diagnostics, USA). r2 = 0.78 and p,0.001.
doi:10.1371/journal.pone.0048452.g001
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3.2 Assay Performance for the NT-proBNP AlphaLISA(R)
Immunoassay
The performance characteristics of the NT-proBNP immuno-
assay is summarised in Table 2. Intra- and inter-assay coefficients
of variation (CVs) for the NT-proBNP immunoassays were below
10%. The LOD for the salivary immunoassay was approximately
16 pg/mL.
3.3 Comparative Analysis of NT-proBNP Immunoassay
with a Commercially Available Assay
In total, 37 plasma samples that have been previously measured
for NT-proBNP levels (concentration ranges between 5 pg/mL to
42,150 pg/mL) were analysed using the two methods. The results
are shown in Figure 1.
3.4 The Effect of Concentrating Saliva Samples
Salivary NT-proBNP concentrations from 18 HF patients were
initially below the LOD of our immunoassay (16 pg/mL). Upon
concentrating saliva samples, we detected NT-proBNP above the
LOD (10 saliva sample from HF patients with 27.1 pg/mL to
243.8 pg/mL) and no NT-proBNP levels were detected in the
filtrates. Furthermore, NT-proBNP was not detected in both
concentrated saliva samples (concentrates and filtrates) collected
from healthy controls who were young and old.
3.5 Salivary NT-proBNP Concentrations in the Healthy
Control Subjects and HF Patients
The salivary NT-proBNP concentrations from the 40 healthy
participants were below the LOD, ,16 pg/mL. The NT-proBNP
concentration in the saliva samples of the HF patients (n = 45)
ranged from 18.3 pg/mL to 748.7 pg/mL with a median value of
76.8 pg/mL (interquartile range (IQR), 28.35 pg/mL to
114.7 pg/mL) (Figure 2A).
The clinical sensitivity and specificity of the salivary NT-
proBNP immunoassay was 82.2% and 100% respectively, with an
overall diagnostic accuracy of 90.6%. The positive predictive value
for the salivary immunoassay was 100%, and negative predictive
value was 83.3%.
3.6 Salivary vs. Plasma NT-proBNP Concentrations in the
HF Population
The NT-proBNP concentration in the plasma samples ranged
from 486 pg/mL to 97,319 pg/mL, with a median of 22731 pg/
mL (IQR, 5386 pg/mL to 36833 pg/mL). There was no
correlation between salivary NT-proBNP and plasma NT-proBNP
concentrations in the HF patients (Figure 2B). The correlation of
NT-proBNP concentration in plasma and saliva are as follow:
n = 45; r2 = 0.006, p = 0.66.
Discussion
To our knowledge this is the first time NT-proBNP has been
measured in saliva samples collected from healthy subjects and HF
patients. Pooled saliva from healthy control spiked with known
concentrations of recombinant NT-proBNP had a recovery of
85% (Table 2). This recovery is a good indication that the NT-
poBNP immunoassay is suitable for use with saliva samples. NT-
proBNP was detected in the saliva samples from HF patients
(sensitivity of 82.22%) but it was not detected in saliva samples
from healthy control subjects. The results suggest that the presence
of NT-proBNP in saliva is specific for the presence of HF. The
need to concentrate 10 of the saliva samples from HF patients
before the detection of NT-proBNP, suggested the presence of
endogenous salivary proteins or mucins (.30 K Dalton) that could
reduce the analytical sensitivity or these proteins by blocking
binding sites of our bead based salivary NT-proBNP immunoas-
say.
Figure 2. The comparison of the plasma and salivary NT-proBNP concentrations for HF patients (n =45). (A), NT-proBNP levels in saliva
of HF patients (n = 45) and healthy participants (n = 40). (B), The correlation of NT-proBNP concentrations in plasma and saliva of HF patients
measured by our NT-proBNP immunoassay.
doi:10.1371/journal.pone.0048452.g002
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Salivary NT-proBNP concentrations is approximately .200-
fold lower than plasma NT-proBNP concentrations. This limita-
tion underlines the importance of using a highly sensitive assay,
such as AlphaLISA(R) bead based immunoassay or possibly
microchip assay systems, which enable the detection of extremely
low concentrations of NT-proBNP. The poor correlation between
NT-proBNP levels in plasma and saliva may suggest that the
movement of heterogeneous NT-proBNP from the blood circu-
lation into the saliva may be impaired in HF patients. Recent work
by Semenov et al., has indicated that HF patients tend to have a
less efficient mechanism of converting proBNP (precursor mole-
cule) by furin convertase into NT-proBNP and BNP upon
secretion from cardiomyocytes into the blood circulation [30].
While furin is also present in the human saliva, its enzymatic
activity in saliva is inhibited by histatins [31], which prevents in
situ generation of salivary NT-proBNP. The levels of measured
NT-proBNP were much lower in saliva, possibly due to the
existence of a threshold level for the movement of unprocessed
proBNP to saliva. Another possible explanation for the reduced
sensitivity of saliva NT-proBNP to detect HF may be the presence
of NT-proBNP with truncated N and/or C termini that was
undetected by our immunoassay which utilised monoclonal
antibodies that targeted the N (1–12AA) and C (63–76AA) termini
of NT-proBNP. Kopsala et al., have demonstrated that NT-
proBNP in the blood circulation is extremely heterogeneous due to
truncations at both termini of this molecule [8]. However, this is
less likely as we observed a significant correlation between plasma
NT-proBNP measured by both the Roche assay and our NT-
proBNP immunoassay. Nevertheless, the result could suggest that
the movement of NT-proBNP from the circulation to the saliva
may vary in HF patients, and remained undetectable in the
unconcentrated samples of saliva of 8 HF patients with elevated
plasma NT-proBNP concentrations.
The undetected levels of salivary NT-proBNP in healthy control
subjects suggest the existence of a physiological cut-off level
(,16 pg/mL, the detection limit of the immunoassay) for the
movement of plasma NT-proBNP into saliva. This may represent
an advantage in population screening where a highly specific test is
required [32]. Given that NT-proBNP is detectable in plasma
samples taken from healthy control subjects [33], studies that have
evaluated the utility of plasma natriuretic peptides to screen for HF
precursors, such as asymptomatic left ventricular systolic dysfunc-
tion, have resulted in unnecessary, downstream testing driven by
high false-positive rates [32]. Attempts to improve specificity by
using urinary natriuretic peptide levels or additional biomarkers
have had variable success [34,35]. If subsequent studies confirm
our findings, salivary NT-proBNP could represent a cost-effective
approach to population screening by avoiding the need for
phlebotomy and sample processing, and minimising unnecessary,
downstream investigations.
In summary, we have demonstrated that NT-pro-BNP is
detectable in saliva and that the levels were higher in a selected
group of HF patients compared with healthy control subjects.
Although, the correlation with plasma is not as strong, its clinical
utility needs to be investigated in more detail using larger,
unselected population studies before more defined cut off limits
can be recommended.
Author Contributions
Conceived and designed the experiments: JYYF YW KK AA JA JCW GD
CP. Performed the experiments: JYYF YW KK AA JA JCW GD CP.
Analyzed the data: JYYF YW KK AA JA JCW GD CP. Contributed
reagents/materials/analysis tools: JYYF YW KK AA JA JCW GD CP.
Wrote the paper: JYYF YW KK AA JA JCW GD CP.
References
1. Bui AL, Horwich TB, Fonarow GC (2011) Epidemiology and risk profile of
heart failure. Nature reviews. Cardiology 8: 30–41.
2. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, et al. (2010)
Executive summary: heart disease and stroke statistics–2010 update: a report
from the American Heart Association. Circulation 121: 948–954.
3. McGrady M, Krum H (2009) Screening: the new frontier in heart failure
management. Cardiovascular therapeutics 27: 1–3.
4. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, et al.
(2008) ESC Guidelines for the diagnosis and treatment of acute and chronic
heart failure 2008. European Journal of Heart Failure 10: 933–989.
5. Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ, et al. (2006)
Guidelines for the prevention, detection and management of people with chronic
heart failure in Australia 2006. The Medical journal of Australia 185: 549–549.
6. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, et al. (2001)
ACC/AHA guidelines for the evaluation and management of chronic heart
failure in the adult: executive summary. Journal of the American College of
Cardiology 38: 2101–2113.
7. Clerico A, Giannoni A, Vittorini S, Passino C (2011) Thirty years of the heart as
an endocrine organ: physiological role and clinical utility of cardiac natriuretic
hormones. Am J Physiol Heart Circ Physiol 301: H12–20.
8. Ala-Kopsala M, Magga J, Peuhkurinen K, Leipala J, Ruskoaho H, et al. (2004)
Molecular heterogeneity has a major impact on the measurement of circulating
N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem 50:
1576–1588.
9. Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg SM, et al.
(2007) Immunoreactivity and guanosine 39,59-cyclic monophosphate activating
actions of various molecular forms of human B-type natriuretic peptide.
Hypertension 49: 1114–1119.
10. Thygesen K, Mair J, Mueller C, Huber K, Weber M, et al. (2012)
Recommendations for the use of natriuretic peptides in acute cardiac care: A
position statement from the Study Group on Biomarkers in Cardiology of the
ESC Working Group on Acute Cardiac Care. Eur Heart J 33: 2001–2006.
11. Clerico A, Fontana M, Zyw L, Passino C, Emdin M (2007) Comparison of the
diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part
of the propeptide of BNP immunoassays in chronic and acute heart failure: a
systematic review. Clinical chemistry 53: 813–822.
12. Mueller C (2007) Comparison of the diagnostic accuracy of BNP and NT-
proBNP in acute and chronic heart failure. Clinical chemistry 53: 1719–1720.
13. Prontera C, Zucchelli GC, Vittorini S, Storti S, Emdin M, et al. (2009)
Comparison between analytical performances of polyclonal and monoclonal
electrochemiluminescence immunoassays for NT-proBNP. Clinica Chimica
Acta 400: 70–73.
14. Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, et al. (2003)
Multicenter evaluation of the Roche NT-proBNP assay and comparison to the
Biosite Triage BNP assay. Clin Chim Acta 338: 107–115.
15. Hu S, Li Y, Wang J, Xie Y, Tjon K,et al. (2006) Human Saliva Proteome and
Transcriptome. Journal of Dental Research 85: 1129–1133.
16. Mohammed R, Leigh Cambell J, Cooper-White J, Dimesky G, Punyadeera C
(2012) The impact of saliva collection and processing methods on Crp, Ige, and
Myoglobin immunoassays. Clinical and Translational Medicine 1: 19.
17. Punyadeera C, Dimeski G, Kostner K, Beyerlein P, Cooper-White J (2011) One-
step homogeneous C-reactive protein assay for saliva. Journal of Immunological
Methods 373: 19–25.
18. Topkas E, Keith P, Dimeski G, Cooper-White J, Punyadeera C (2012)
Evaluation of saliva collection devices for the analysis of proteins. Clin Chim
Acta 413: 1066–1070.
19. Kiyosawa K, Sodeyama T, Tanaka E, Nakano Y, Furuta S, et al. (1991)
Hepatitis C in hospital employees with needlestick injuries. Annals of internal
medicine 115: 367–369.
20. Oksenhendler E, Harzic M, Le Roux JM, Rabian C, Clauvel JP (1986) HIV
Infection with Seroconversion after a Superficial Needlestick Injury to the
Finger. The New England Journal of Medicine 315: 582–582.
21. Pfaffe T, Cooper-White J, Beyerlein P, Kostner K, Punyadeera C (2011)
Diagnostic Potential of Saliva: Current State and Future Applications. Clin
Chem 57: 675–687.
22. Palmer SC, Yandle TG, Nicholls MG, Frampton CM, Richards AM (2009)
Regional clearance of amino-terminal pro-brain natriuretic peptide from human
plasma. Eur J Heart Fail 11: 832–839.
23. Pemberton CJ, Johnson ML, Yandle TG, Espiner EA (2000) Deconvolution
analysis of cardiac natriuretic peptides during acute volume overload.
Hypertension 36: 355–359.
24. Kaufman E, Lamster IB (2002) The Diagnostic Applications of Saliva– A
Review. Critical Reviews in Oral Biology & Medicine 13: 197–212.
Relevance of Salivary NT-ProBNP and Heart Failure
PLOS ONE | www.plosone.org 5 October 2012 | Volume 7 | Issue 10 | e48452
25. Navazesh M (1993) Methods for collecting saliva. Ann N Y Acad Sci 694: 72–77.
26. Poll EM, Kreitschmann-Andermahr I, Langejuergen Y, Stanzel S, Gilsbach JM,
et al. (2007) Saliva collection method affects predictability of serum cortisol. Clin
Chim Acta 382: 15–19.
27. Jaedicke KM, Taylor JJ, Preshaw PM (2012) Validation and quality control of
ELISAs for the use with human saliva samples. J Immunol Methods 377: 62–65.
28. Armbruster DA, Pry T (2008) Limit of blank, limit of detection and limit of
quantitation. Clin Biochem Rev 29 Suppl 1: S49–52.
29. Hart A (2001) Mann-Whitney test is not just a test of medians: differences in
spread can be important. BMJ 323: 391–393.
30. Semenov AG, Tamm NN, Seferian KR, Postnikov AB, Karpova NS, et al.
(2010) Processing of pro-B-type natriuretic peptide: furin and corin as candidate
convertases. Clinical chemistry 56: 1166–1176.
31. Basak A, Ernst B, Brewer D, Seidah NG, Munzer JS, et al. (1997) Histidine-rich
human salivary peptides are inhibitors of proprotein convertases furin and PC7
but act as substrates for PC1. The journal of peptide research : official journal of
the American Peptide Society 49: 596.
32. Atherton JJ (2012) Stage B heart failure: rationale for screening. Heart Fail Clin
8: 273–283.
33. Shi X, Xu G, Xia T, Song Y, Lin Q (2005) N-terminal-pro-B-type natriuretic
peptide (NT-proBNP): Reference range for Chinese apparently healthy people
and clinical performance in Chinese elderly patients with heart failure. Clinica
Chimica Acta 360: 122–127.
34. Ng LL, Pathik B, Loke IW, Squire IB, Davies JE (2006) Myeloperoxidase and C-
reactive protein augment the specificity of B-type natriuretic peptide in
community screening for systolic heart failure. American Heart Journal 152:
94–101.
35. Ng LL, Loke IW, Davies JE, Geeranavar S, Khunti K, et al. (2005) Community
screening for left ventricular systolic dysfunction using plasma and urinary
natriuretic peptides. Journal of the American College of Cardiology 45: 1043–
1050.
Relevance of Salivary NT-ProBNP and Heart Failure
PLOS ONE | www.plosone.org 6 October 2012 | Volume 7 | Issue 10 | e48452
